The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde

Volumn 100, Issue 12, 2010, Pages 808-809

  Abdool Karim, Quarraisha ^a   Abdool Karim, Salim S ^b   Baxter, Cheryl ^b   Friedland, Gerald ^b   Gengiah, Tanuja ^b   Gray, Andrew ^b   Grobler, Anneke ^b   Naidoo, Kogileum ^b   Padayatchi, Nesri ^b   El Sadr, Wafaa ^b  

^a Centre for AIDS Programme of Research in Africa   (South Africa)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT;

CLINICAL TRIAL (TOPIC); DRUG COMBINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; REVIEW; SOUTH AFRICA; TUBERCULOSIS;

ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HUMANS; SOUTH AFRICA; TUBERCULOSIS;

MLCS; MLOWN;

EID: 79955077106     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/samj.4621     Document Type: Review

References (0)